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ABSTRACT 
Diabetes mellitus (DM) is a serious and growing 
worldwide health problem and is associated with se- 
vere acute and chronic complications that negatively 
influence both quality of life and survival of affected 
individuals. It is a heterogeneous deregulation of car- 
bohydrate metabolism. The liver is a central regulator 
of carbohydrate homeostasis and releases glucose 
according to metabolic demands. In the last years, the 
liver injury has been recognized as a major complica- 
tion of DM. In fact, evidence suggests that in diabetic 
patients, the mortality rate due to liver cirrhosis is 
even higher than that due to cardiovascular disease 
and it has been suggested that there is a two-fold in- 
creased risk of liver disease in diabetic patients. Among 
the different types of diabetes, we analyze type 1 dia- 
betes mellitus as a chronic disorder and an inflam- 
matory process, which is also associated with in- 
creased risk of chronic liver injury. Animal models 
have contributed extensively to the study of diabetes, 
and it is well established that administration of a 
unique dose of streptozotocin (STZ) induces insulin- 
dependent type 1 diabetes mellitus. We analyzed the 
contribution of Tumor Necrosis Factor alpha (TNF-α) 
intracellular pathway and oxidative stress in the de- 
velopment of apoptosis in the liver of streptozotocin- 
induced diabetic animals. In this review, we describe 
the role of upstream mediators of the interaction be- 
tween TNF-α and its receptor, TNF-R1, by assessing 
the ability of the in vivo treatment with etanercept 
(TNF-α blocking antibody) to protect against TNF-α- 
induced apoptosis. Also, we studied the role of iNOS- 
induction in the TNF-α-induced liver apoptosis by 
type 1 diabetes, by treatment of diabetic rats with 
aminoguanidine (selective iNOS inhibitor), which 
blocked the induction of apoptosis. Interestingly, 
iNOS inhibition significantly reduced TNF-α levels, 
evidencing an interaction between TNF-α and iNOS 
activity. On the other hand, we found that the ad- 
ministration of antioxidants/hydroxyl radical scaven- 
gers (Tempol and Desferal) prevented oxidative stress 
by reducing the effects of hydroxyl radical production 
and both lipid peroxidation (LPO) levels and apop- 
tosis. Taken together, our studies support that, at least 
in part, the hydroxyl radical acts as a reactive inter- 
mediate, which leads to liver apoptosis in a model of 
STZ-mediated hyperglycemia. Conclusion and Future: 
The relevance of the present review is to provide fur- 
ther knowledge about the mechanisms which may 
contribute to the disease process in the liver during 
the course of an inflammatory process as it is type 1 
diabetes. Regulation of hepatic TNF-α levels and oxi- 
dative stress in the diabetic state could be of thera- 
peutic relevance for the improvement or delay of the 
hepatic complications linked to chronic hyperglycemia.  
 
Keywords: Diabetes Mellitus (DM); Liver; Apoptosis, 
Inflammation; TNF-α; iNOS; NO; Oxidative Stress;  
Hydroxyl Radical 
1. INTRODUCTION 
After food intake, blood glucose levels rise and insulin is 
released by the pancreas to maintain homeostasis. In the 
diabetic state, the absence or deficient action of insulin in 
target tissues is the cause of hyperglycemia and abnor- 
malities in the metabolism of proteins, fats and carbo- 
hydrates. In addition, chronic hyperglycemia, a hallmark 
of diabetes, is responsible for organic dysfunction, being 
eyes, kidneys, nervous system, heart and blood vessels 
the most important organs affected. Diabetes mellitus 
(DM) is a heterogeneous deregulation of carbohydrate 
metabolism, characterized by chronic hyperglycemia that 
results from impaired glucose metabolism and the sub-*Corresponding author. 
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sequent increase in blood serum glucose concentration. 
The pathogenic equation for DM presents a complex 
interrelation of metabolic, genetic and environmental 
factors, as well as inflammatory mediators. Among the 
latter, it is mostly unclear whether they reflect the dis- 
ease process or are simply signs of systemic or local re- 
sponses to the disease [1]. 
Currently diabetes is classified into: 1) Type 1 diabetes 
which is an autoimmune disease influenced by genetic 
and environmental factor. It is characterized by destruc- 
tion of pancreatic beta cells mediated by T cells that 
leads to partial or total absence of insulin secretion. The 
presence of auto-antibodies associated with diabetes is 
the most reliable marker of the existence of the disease 
although there is no evidence that they are the cause of 
the disease, 2) Type 2 diabetes in which there is a resis- 
tance state resulting from inefficient use of insulin by the 
tissues to regulate blood glucose concentration [2], 3) 
Gestational diabetes is a different entity and is defined as 
diabetes diagnosed for first time during pregnancy [3]. 
Other forms of diabetes have been genetically character- 
ized, for example, onset diabetes of the maturity of the 
young (MODY) that is a familiar form of diabetes that is 
inherited in an autosomal dominant mutation associated 
with beta cells or liver specific genes such glucokinase. 
Other form well characterized of diabetes is called “sec- 
ondary diabetes” and includes those associated with: pan- 
creatic disease, hemochromatosis, excess steroids or other 
hormones, certain drugs (e.g., protease inhibitors), ge- 
netic defects in insulin action, endocrinopathies, infec-
tion, and also forms of diabetes uncommon mediated by 
immunologic mechanisms. The common symptoms of 
different forms of diabetes are polyuria, polydipsia and 
polyphagia with weight loss and in some cases, blurred 
vision [3]. 
DM affects about 26 million individuals in America 
and at least 250 million people worldwide (World Health 
Organization), causing about 5% of all deaths. Besides, 
the number of affected people is expected to duplicate by 
2030 unless urgent measures are taken [4,5]. Every day, 
200 children under 14 years are affected by type 1 dia- 
betes, and this number increases by 3 per cent each year, 
whereas the analogous increment for preschool children 
reaches 6 per cent [6]. All these data point out the epi- 
demic character of DM. 
2. ANIMAL MODELS FOR DIABETES 
STUDY 
Rats and mice are animals commonly used for studying 
the effects of diabetes. Type 2 DM can be induced in 
animal models through dietary modification such as the 
administration of sucrose, fructose, high fat diet and 
glucose infusion or through genetic manipulation such as 
db/db mice, ob/ob mice, Goto-Kakizaki rats, Zucker 
diabetic rats and BHE rats [7]. 
On the other hand, type 1 diabetes can be replicated in 
animal models through genetic modifications i.e. non 
obese diabetic mice (NOD), which spontaneously de- 
velop type 1 diabetes in a manner similar to humans [7]. 
Other animal models genetically selected are the Bio 
Breeding rats (BB), in which the pancreatic islets are 
under the attack of immune T cells, B cells, macrophages 
and natural killer cells. At approximately 12 weeks of 
age, these diabetic rats presented weight loss, polyuria, 
polyphagia, hyperglycemia and insulinopenia. As in hu- 
mans, if these rats are not treated with exogenous insulin, 
ketoacidosis is severe and fatal [8]. Another way to ob- 
tain experimental animals with type 1 diabetes involves 
the administration of diabetogenic chemicals such as 
alloxan or streptozotocin [9,11]. In our laboratory, we 
have shown that treatment with streptozotocin (STZ) 
causes alterations in biliary excretion during the first 
seven days post-injection of the drug, and that biliary 
function is normalized 10 days after injection [10,12]. 
This is the reason why studies of liver function during 
STZ-induced diabetic state should be performed fifteen 
days after injection of STZ. In our work, STZ-induced 
diabetes (SID) was achieved by a single dose of STZ (60 
mg/kg body weight, i.p., in 50 mM citrate buffer, pH 4.5). 
Control rats were injected with vehicle alone. Fifteen 
days after STZ injection, a time when the toxic effect of 
the drug on the liver has disappeared [9,10], serum glu- 
cose levels were tested by means of the glucose oxidase 
method (Wiener Lab., Rosario, Argentina) in samples of 
diabetic and control animals. Successful induction of 
diabetes was defined as a blood glucose level >13.2 
mmol/l. 
3. DIABETES AND INFLAMMATION 
Inflammation represents a protective response that con- 
trols infections and promotes tissue repair, but it can also 
contribute to local tissue damage in a broad spectrum of 
inflammatory disorders. The inflammatory responses are 
associated with variations of a broad array of plasma 
proteins and pro-inflammatory cytokines. The acute- 
phase response is a systemic reaction in which the con- 
centration of a variety of plasma proteins, termed acute- 
phase proteins, may increase or decrease in response to 
inflammation [13]. Plasma concentrations of acute-phase 
proteins are largely dependent on the hepatic biosynthe- 
sis of such proteins, and changes in their production are 
influenced by pro-inflammatory cytokines, such as inter- 
leukin (IL) IL-1, IL-6 and tumor necrosis factor alpha 
(TNF-α). These cytokines are produced during the in- 
flammatory process and are principal stimulators of 
acute-phase proteins and other markers of chronic in- 
flammation commonly detected in cardiovascular dis- 
eases, diabetes mellitus, osteoarthritis and rheumatoid 
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arthritis [14,15]. 
The chronic hyperglycemia can directly promote an 
inflammatory state, where the increase in cytokines can 
lead to destruction of the pancreatic beta cells and mal- 
function of the endocrine pancreas in both type 1 and 
type 2 diabetes [16]. There is evidence that autocrine 
insulin exerts protective anti-apoptotic effects on beta 
cells and inhibits the suppressor of cytokine signaling 
(SOCS) induced by various cytokines and leads to the 
apoptosis of the beta cell [17]. 
Commonly, type 1 and type 2 DM are considered in- 
flammatory processes [18,19] as there is a significant 
increase in IL-6, IL-18, IL-1 and TNF-α in the blood of 
patients with this disease [20,21]. Furthermore, chemokines 
(ligands 2 and 5 chemokines CCL2, CCL5 and CX3CL1), 
intercellular adhesion molecule-1 (ICAM-1), vascular 
cell adhesion molecule-1 (VCAM-1) and nuclear tran- 
scription factor κB (NFκB) are involved in the develop- 
ment and progression of the disease [22,23]. 
4. DIABETES AND OXIDATIVE STRESS 
Oxidative stress, also referred to as a reactive oxygen 
species (ROS)/antioxidant imbalance, occurs when the 
net amount of ROS exceeds the antioxidant capacity. 
Thus, oxidative stress can occur because of a general 
increase in ROS generation, a depression of the antioxi- 
dant systems, or both. ROS derived from various oxida- 
tion pathways can generate products leading to cellular 
deregulation. ROS mainly includes superoxide anion 
( 2O ), hydrogen peroxide (H2O2) and hydroxyl radical 
(HO.), which results in the production of other free radi- 
cals for example, nitric oxide (NO) and peroxinitrite 
(ONOO.), also called reactive nitrogen species (RNS) 
[24,25]. 2  can be generated by specialized enzymes, 
such as the nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase and then can be converted to H2O2 in 
the presence of superoxide dismutase (SOD). In the 
presence of high iron (Fe+3), H2O2 can be reduced, re-
sulting in the generation of hydroxyl radical. NO is gene- 
rated through nitric oxide synthase (NOS). 2  can also 
react with NO to form the highly reactive ONOO [26]. 

O
O
Under normal conditions, the body has a potent anti- 
oxidant system to that protects it from the deleterious 
effects of ROS. When either the production of ROS is 
increased or the antioxidant defenses inactivated, oxida- 
tive stress occurs and ROS can react with cellular mac- 
romolecules and enhance the process of lipid peroxida- 
tion (LPO), cause DNA damage and/or induce protein 
and nucleic acid modifications [27,28]. ROS generation 
has been implicated in the pathogenesis of various dis- 
ease states, including atherosclerosis and inflammation 
[29-33]. 
Chronic hyperglycemia causes increased formation of 
advanced glycated end products, increased glucose auto- 
oxidation and oxidative phosphorylation, which lead to 
oxidative stress. It is well established that hyperglycemia 
elicits an increase in ROS production, due to increased 
input reducing equivalents into the mitochondrial elec-
tron transport chain [34]. Thus, hyperglycemia-induced 
oxidative stress or activation of other pathways may 
cause tissue damage. 
West indicated an increase in oxidative damage in 
both type 1 and type 2 diabetes as well as deficits in an- 
tioxidant defense enzymes and vitamins. It is argued that 
oxygen, antioxidant defenses, and cellular redox status 
should be regarded as central players in diabetes [35].  
Mitochondrial dysfunction is considered to be a criti-
cal component in the development of insulin resistance 
and type 1 diabetes such as STZ-induced diabetic (SID) 
rats and mice where hyperglycemia induces an accelera-
tion of hydroxyl radical generation and this has been 
correlated with the level of thiobarbituric acid thiobarbi- 
turic acid reactive compounds (TBARS) reactive com- 
pounds as an estimation of LPO [36,37]. In this connec-
tion, we have demonstrated that hyperglycemia increases 
the hydroxyl radical production in the liver of STZ-in- 
duced diabetic rats [38]. In addition, the increase in oxi- 
dative stress induced by hyperglycemia and inflamma- 
tion conduces to the development of associated diseases, 
such as diabetic nephropathy [18,22]. 
5. NITRIC OXIDE IN TNF-α PATHWAYS 
AND APOPTOSIS 
As stated above, one of the main cytokines released in 
these inflammatory processes is TNF-α, which can acti-
vate signaling pathways associated with cell survival, 
apoptosis, inflammatory response and cell differentiation. 
The induction of the responses mediated by TNF-α oc-
curs through the binding of the cytokine to the receptors 
TNF-R1 and TNF-R2. Both receptors may mediate cell 
death. TNF-R1 contains a death domain while TNF-R2 
does not but it would enhance the cytotoxic effects of 
TNF-R1. In response to inflammation and infection, TNF-α 
is produced primarily by immune system cells such as 
macrophages and lymphocytes [39,40]. The binding of 
TNF-α to TNF-R1 can promote the activation of NFκB 
or initiate the activation of caspases, which play a major 
role in the execution of programmed cell death or apop-
tosis [41]. NFκB stimulates the expression of genes en- 
coding cytokines (e.g. TNF-α, IL-1, IL-6, IL-2, IL-12, 
INF- and CM-CSF), cell adhesion molecules (CAMs), 
chemokine receptors and inducible enzymes (e.g., COX- 
2, iNOS). It also increases the expression of molecules 
involved in regulating cell proliferation, apoptosis and 
cell cycle progression, such as the cellular inhibitor of 
apoptosis protein 1 (c-IAP1), c-IAP2, TNF-receptor-as- 
sociated factor 1 (TRAF-1), TRAF-2, B-cell lymphocyte/ 
leukemia-2 (Bcl-2), Fas, c-myc and cyclin D1 [42,43]. It 
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has been found that high levels of glucose can cause 
apoptosis, in part, through activation of NFκB [44]. It 
has been shown that high glucose levels activate protein 
kinase C (PKC) pathway, NFκB and ROS [45-47]. Fur-
thermore, cytokines and bacterial pathogens can activate 
iNOS and generate large concentrations of NO, through 
activation of NFκB [7]. 
6. REACTIVE OXYGEN SPECIES IN 
MODULATION OF APOPTOSIS 
Apoptosis is a tightly regulated form of cell death in 
which a cell effectively partakes in its own demise. The 
programmed cell death is an essential physiological process 
required for normal development and maintenance of 
tissue homeostasis execution of the death program is 
characterized by morphological changes which includes 
blebbing, chromatin condensation, nuclear fragmentation, 
loss of adhesion and rounding and cell shrinkage. Bio- 
chemical features associated with apoptosis include high 
molecular weight, deoxyribonucleic acid (DNA) frag- 
mentation and/or fragmentation into an oligonucleosomal 
ladder, phosphatidyl serine externalization, proteolytic 
cleavage of a number of intracellular substrates and mi- 
tochondrial permeability transition pore (MPTP) assem- 
bly [48]. Apoptotic cells are detected in organs, such as 
the liver, during development as well as in healthy adults. 
Increases of apoptotic cells are present in many chronic 
inflammatory and autoimmune diseases.  
Oxidative stress occurs in cells when the generation of 
ROS overwhelms the cell’s natural antioxidant defenses. 
Moreover, the oxidative stress and the redox state of a 
cell play a pivotal role in regulating apoptosis [49]. The 
role of ROS in the induction of apoptosis is provided by 
several studies in which the addition of ROS in low lev- 
els induces apoptosis and the observation that various 
antioxidants can inhibit cell death [50,52]. Oxidative 
stress can lead to damage of the mitochondrial inner 
membrane, resulting in MPTP formation and subsequent 
release of cytochrome c and apoptosis inducing factor 
from the mitochondria. In the cytosol, cytochrome c 
complexes with Apaf-1 to activate procaspase 9, which 
in turn activates downstream effector caspases (3, 6 and 
7) [53]. Furthermore, the MPTP is regulated by the rela- 
tive prevalence of anti-apoptotic (Bcl-2, Bcl-XL) or pro- 
apoptotic (Bad, Bax) Bcl-2 family members into the mi- 
tochondrial membrane [54]. 
The initial cellular response to high glucose challenge 
is the generation of ROS, which rapidly induces apop- 
totic cell death [55]. It is known that high D-glucose in- 
duces endothelial apoptosis through activation of the 
Bax-caspase proteases pathway. The effectors of apop- 
tosis are now well known to be represented by a family 
of intracellular cysteine proteases known as caspases 
[56]. A feature of apoptosis that impinges on caspases is 
altered mitochondrial function characterized by a reduc- 
tion in the electrochemical gradient across the mitochon- 
drial membrane and a release of mitochondrial cyto- 
chrome c to cytoplasm, and it is inhibited by the presence 
of Bcl-XL in these organelles [47,57]. Translocation of 
pro-apoptotic Bax protein into the mitochondrial mem- 
brane is accompanied by a significant increase in cas- 
pase-3 and caspase-9 activities [58]. 
7. DIABETES AND LIVER APOPTOSIS 
The onset of diabetes is accompanied by development of 
major biochemical and functional abnormalities in the 
liver, including alterations in carbohydrate, lipid, and 
protein metabolism, and changes in antioxidant status 
[59-62]. The prevalence of hepatobiliary diseases is in- 
creased in patients with either type 1 or type 2 diabetes 
[62,63]. 
Diabetes is known to be a major disorder in which 
oxidative stress and TNF-α production have been impli-
cated through several lines of evidence [34,64,66]. ROS 
and TNF-α have been defined as an autocatalytic mecha-
nism that can lead to programmed cell death (apoptosis) 
[67]. 
Regulation of cell death by apoptosis may be another 
determinant of liver structure and lesion formation [68]. 
It has become increasingly clear that the process of cell 
death by apoptosis is a relatively ubiquitous phenomenon 
in a variety of cell types, including hepatic cells [69]. 
In a research recently published by us, it is demon-
strated that the diabetic state induces an increase of 
TNF-α and of its receptor TNF-R1 in the liver [65]. Fol-
lowing TNF-α binding to the TNF-R1, an adaptor mole-
cule (TRADD, TNF receptor associated DD protein), is 
recruited by the dead domain (DD) to form the first pro-
tein complex, which also includes TRAF2 [70]. This 
complex then dissociates from TNF-R1 and forms a dif-
ferent complex in the cytosol, which binds FADD (Fas 
associated DD protein), and then recruits caspase-8. 
Cleavage of pro-caspase 8 allows the release of activated 
caspase-8 [71]. Caspase-8 can cleave Bid to form an ac-
tive fragment, t-Bid [72]. In the liver of STZ-induced 
diabetic rats we observed an increase in the pathway that 
begins with the triggering of receptor TNF-R1 by TNF-α, 
demonstrated by increased expression and activity of 
caspase-8 and mitochondrial t-Bid [63]. Pro-apoptotic 
protein Bid promotes initiation of the mitochondrial 
death pathway with release of cytochrome c, and activa-
tion of effectors caspase-3 that ultimately induce apop-
tosis [73]. Our results clearly demonstrated that in the 
liver of STZ-induced diabetic rats induces an enlarge-
ment of caspase-3 activity with the consequent increase 
in the apoptosis index. Besides, the anti–TNF-α (etaner-
cept) treatment produced a declination in the response of 
receptor TNF-R1 to TNF-α (diminished caspase-8 ex-
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for iNOS. pression and activity and mitochondrial protein t-Bid, in 
comparison with SID group) showing a reduction of the 
cascade of events leading to apoptotic cell death [65]. 
In the liver of diabetic rats, we found an increase in 
TNF-α due to an increased expression of iNOS, which 
led to a high production of NO [65]. Similar results have 
been reported in different tissues by other authors [77,78]. 
We observed that the treatment with etanercept, which 
blocks TNF-α, leads to a decrease in the expression of 
iNOS, which is increased in the diabetic state. Further- 
more, the mentioned treatment reduces the production of 
NO in the liver of STZ-induced diabetic rats. It has been 
shown that high concentrations of glucose cause an in- 
crease in the expression of iNOS induced by cytokines in 
rat tissues [79]. Consistent with this, high glucose con- 
centrations do not increase iNOS in the absence of 
TNF-α [65]. The inhibition of iNOS with a selective in- 
hibitor, such as aminoguanidine, also reduced the pro- 
duction of TNF-α, thus evidencing an interaction between 
TNF-α pathway and the activity of iNOS. In addition, the 
treatment with aminoguanidine decreases caspase-8 and 
caspase-3 activities, resulting in effective blockade of 
apoptosis in the liver of STZ-diabetic rats [65]. 
An early study had demonstrated that the activation of 
JNK is associated with increased TNF-α induced apop- 
tosis hepatocytes [74]. In this connection, ours studies 
demonstrated that the diabetes leads to the activation of 
JNK, inducing an increase of the apoptotic index. More- 
over, we have demonstrated that the diminution of TNF-α 
levels by the treatment with etanercept seems to com- 
pletely abolish the observed the activation of JNK in- 
duced by the diabetic state, leading to the diminution of 
the apoptosis [63]. 
The increase of the TNF-α level in the liver of STZ- 
induced diabetic rats leads to a marked up-regulation of 
the NFκB pathway. NFκB is one of the key transcription 
factors involved in triggering the cascade of events that 
allow inflammation and different research groups have 
demonstrated its activation in the diabetic liver [75,76]. 
The expression of iNOS is closely related to stimulation 
of NFκB. Indeed, NFκB recognition sites have been 
identified in the promoter region of the gene encoding  Our studies demonstrate that in the diabetic liver oc-  
 
 
 
Figure 1. Proposed scheme for the mechanism involved in the hyperglycemia-induced apoptosis that occurs 
in type 1 diabetes-induced liver disease. In the diabetic state, the increase in hepatic TNF-α induces activation 
of NFκB, caspase-8 and JNK, which leads to an increase in apoptotic events. Besides, hyperglycemia in- 
creases ROS levels, specifically hydroxyl radical, which initiate mitochondrial apoptosis either directly and/or 
by acting through Bcl2 family proteins, thus inducing the formation of the mitochondrial permeability transi-
tion pore (MPTP), the release of cytochrome c and the activation of caspase 3. 
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curs apoptosis. Importantly, we have identified that the 
hydroxyl radical contributes partially to increase mito- 
chondrial Bax protein expression leading to cytochrome 
c release and caspase-3 activation which are associated 
with hyperglycemia-induced liver apoptosis. The strong 
inhibition of the LPO and apoptosis elicited by the 
treatments with Desferal (potent iron chelator) [73] or 
Tempol (direct scavenger of hydroxyl radicals) [74] 
clearly establishes a connection between production of 
hydroxyl radical, the LPO levels and apoptosis [36]. 
At the light of previous knowledge and from our own 
results, we present in Figure 1 a summary of the se- 
quence of events occurring in the hepatocytes of the dia- 
betic liver under hyperglycemic conditions. 
8. CONCLUSION 
The relevance of the present review is to provide further 
knowledge about the mechanisms which may contribute 
to the disease process in the liver during the course of an 
inflammatory process as it is type 1 diabetes. Regulation 
of hepatic TNF-α levels and oxidative stress in the dia- 
betic state could be of therapeutic relevance for the im- 
provement or delay of the hepatic complications linked 
to chronic hyperglycemia. 
9. ACKNOWLEDGEMENTS 
This work was supported by research grants from CONICET. We es- 
pecially wish to thank Dr Cecilia Basiglio for language revision. 
 
REFERENCES 
[1] Pietropaolo, M., Barinas-Mitchell, E., et al. (2007) The 
heterogeneity of diabetes: Unraveling a dispute: Is sys- 
temic inflammation related to islet autoimmunity? Dia- 
betes, 56, 1189-1197. doi:10.2337/db06-0880 
[2] Dey, A. and Swaminathan, K. (2010) Hyperglycemia- 
induced mitochondrial alterations in liver. Life Science, 
87, 197-214. doi:10.1016/j.lfs.2010.06.007 
[3] Tierney, L.M. and M. S. a. P. M. (2002) Current medical 
Diagnosis & Treatment, 1203-1215.  
[4] Kasuga, M. (2006) Insulin resistance and pancreatic beta 
cell failure. Journal of Clinical Investigation, 116, 1756- 
1760. doi:10.1172/JCI29189 
[5] Wild, S., Roglic, G., et al. (2004) Global prevalence of 
diabetes: Estimates for the year 2000 and projections for 
2030. Diabetes Care, 27, 1047-1053.  
doi:10.2337/diacare.27.5.1047  
[6] Shaw, J.E., Sicree, R.A., et al. (2010) Global estimates of 
the prevalence of diabetes for 2010 and 2030. Diabetes 
Research and Clinical Practice, 87, 4-14.  
doi:10.1016/j.diabres.2009.10.007 
[7] Kikutani, H. and Makino, S. (1992) The murine autoim- 
mune diabetes model: NOD and related strains. Advances 
in Immunology, 51, 285-322.  
doi:10.1016/S0065-2776(08)60490-3   
[8] Rees, D.A. and Alcolado, J.C. (2005) Animal models of 
diabetes mellitus. Diabetic Medicine, 22, 359-370.  
doi:10.1111/j.1464-5491.2005.01499.x 
[9] Carnovale, C.E. and Rodriguez Garay, E.A. (1984) Re- 
versible impairment of hepatobiliary function induced by 
streptozotocin in the rat. Experientia, 40, 248-250.  
doi:10.1007/BF01947564  
[10] Carnovale, C.E., Marinelli, R.A., et al. (1986) Bile flow 
decrease and altered bile composition in streptozotocin- 
treated rats. Biochemical Pharmacology, 35, 2625-2628.  
doi:10.1016/0006-2952(86)90063-8   
[11] Mordes, J.P., Bortell, R., et al. (2004) Rat models of type 
1 diabetes: Genetics, environment, and autoimmunity. 
ILAR Journal, 45, 278-291. doi:10.1093/ilar.45.3.278  
[12] Carnovale, C.E., Marinelli, R.A., et al. (1987) Toxic ef- 
fect of streptozotocin on the biliary secretion of nicoti-
namide-treated rats. Toxicology Letters, 36, 259-265.  
doi:10.1016/0378-4274(87)90194-9  
[13] Wellen, K.E. and Hotamisligil, G.S. (2005) Inflammation, 
stress, and diabetes. Journal of Clinical Investigation, 
115, 1111-1119. doi:10.1172/JCI25102 
[14] Dandona, P., Aljada, A., et al. (2004) Inflammation: The 
link between insulin resistance, obesity and diabetes. 
Trends in Immunology, 25, 4-7.  
doi:10.1016/j.it.2003.10.013  
[15] Willerson, J.T. and Ridker, P.M. (2004) Inflammation as 
a cardiovascular risk factor. Circulation, 109, II2-10.  
doi:10.1161/01.CIR.0000129535.04194.38 
[16] Ahrens, B. (2011) Antibodies in metabolic diseases. New 
Biotechnology, 28, 530-537.  
doi:10.1016/j.nbt.2011.03.022 
[17] Venieratos, P.D., Drossopoulou, G.I., et al. (2010) High 
glucose induces suppression of insulin signalling and 
apoptosis via upregulation of endogenous IL-1beta and 
suppressor of cytokine signalling-1 in mouse pancreatic 
beta cells. Cell Signal, 22, 791-800.  
doi:10.1016/j.cellsig.2010.01.003 
[18] Alexandraki, K.I., Piperi, C., et al. (2008) Cytokine se- 
cretion in long-standing diabetes mellitus type 1 and 2: 
Associations with low-grade systemic inflammation. Jour- 
nal of Clinical Immunology, 28, 314-321.  
doi:10.1007/s10875-007-9164-1 
[19] Erbagci, A.B., Tarakcioglu, M., et al. (2001) Mediators 
of inflammation in children with type I diabetes mellitus: 
cytokines in type I diabetic children. Clinical Biochemis- 
try, 34, 645-650. doi:10.1016/S0009-9120(01)00275-2 
[20] Esposito, K., Nappo, F., et al. (2002) Inflammatory cyto- 
kine concentrations are acutely increased by hyperglyce- 
mia in humans: role of oxidative stress. Circulation, 106, 
2067-2072.  
http://www.ncbi.nlm.nih.gov/pubmed/12379575  
[21] Foss, N.T., Foss-Freitas, M.C., et al. (2007) Impaired 
cytokine production by peripheral blood mononuclear 
cells in type 1 diabetic patients. Diabetes & Metabolism, 
33, 439-443. doi:10.1016/j.diabet.2007.10.001 
[22] Elmarakby, A.A. and Sullivan, J.C. (2012) Relationship 
between oxidative stress and inflammatory cytokines in 
Copyright © 2013 SciRes.                                                                       OPEN ACCESS 
D. E. Francés et al. / J. Biomedical Science and Engineering 6 (2013) 645-653 651
diabetic nephropathy. Cardiovascular Therapeutics, 30, 
49-59. doi:10.1111/j.1755-5922.2010.00218.x 
[23] Navarro-Gonzalez, J.F., Muros, M., et al. (2011) Pen- 
toxifylline for renoprotection in diabetic nephropathy: 
The PREDIAN study. Rationale and basal results. Jour- 
nal of Diabetes and Its Complications, 25, 314-319.  
doi:10.1016/j.jdiacomp.2010.09.003 
[24] Fridovich, I. (1995) Superoxide radical and superoxide 
dismutases. Annual Review of Biochemistry, 64, 97-112.  
doi:10.1146/annurev.bi.64.070195.000525 
[25] Selemidis, S., Sobey, C.G., et al. (2008) NADPH oxi- 
dases in the vasculature: Molecular features, roles in dis- 
ease and pharmacological inhibition. Pharmacology & 
Therapeutics, 120, 254-291.  
doi:10.1016/j.pharmthera.2008.08.005 
[26] Wang, K., Brems, J.J., et al. (2011) iNOS/NO signaling 
regulates apoptosis induced by glycochenodeoxycholate 
in hepatocytes. Cell Signal, 23, 1677-1685.  
doi:10.1016/j.cellsig.2011.06.003 
[27] Dean, R.T., Fu, S., et al. (1997) Biochemistry and pa- 
thology of radical-mediated protein oxidation. Bioche- 
mical Journal, 324, 1-18.  
http://www.ncbi.nlm.nih.gov/pubmed/9164834  
[28] Yu, B.P. (1994) Cellular defenses against damage from 
reactive oxygen species. Physiology Review, 74, 139-162.  
http://www.ncbi.nlm.nih.gov/pubmed/8295932 
[29] Ames, B.N., Shigenaga, M.K., et al. (1993) Oxidants, 
antioxidants, and the degenerative diseases of aging. Pro- 
ceedings of the National Academy of Sciences of USA, 90, 
7915-7922. doi:10.1073/pnas.90.17.7915  
[30] Beckman, J.S. and Koppenol, W.H. (1996) Nitric oxide, 
superoxide, and peroxynitrite: the good, the bad, and ugly. 
American Journal of Physiology, 271, C1424-1437.  
http://www.ncbi.nlm.nih.gov/pubmed/8944624  
[31] Buttke, T.M. and Sandstrom, P.A. (1994) Oxidative stress 
as a mediator of apoptosis. Immunology Today, 15, 7-10.  
doi:10.1016/0167-5699(94)90018-3 
[32] Halliwell, B. (1997) Antioxidants and human disease: A 
general introduction. Nutrition Reviews, 55, S44-49.  
http://www.ncbi.nlm.nih.gov/pubmed/9155225  
[33] Wiseman, H. and Halliwell, B. (1996) Damage to DNA 
by reactive oxygen and nitrogen species: Role in inflame- 
matory disease and progression to cancer. Biochemical 
Journal, 313, 17-29.  
http://www.ncbi.nlm.nih.gov/pubmed/8546679  
[34] Brownlee, M. (2001). Biochemistry and molecular cell 
biology of diabetic complications. Nature, 414, 813-820.  
doi:10.1038/414813a 
[35] West, I.C. (2000). Radicals and oxidative stress in diabe- 
tes. Diabetic Medicine, 17, 171-180. 
http://www.ncbi.nlm.nih.gov/pubmed/10784220  
[36] Ohkuwa, T., Sato, Y., et al. (1995) Hydroxyl radical for- 
mation in diabetic rats induced by streptozotocin. Life 
Sciences, 56, 1789-1798.  
doi:10.1016/0024-3205(95)00150-5 
[37] Winiarska, K., Drozak, J., et al. (2004) Diabetes-induced 
changes in glucose synthesis, intracellular glutathione 
status and hydroxyl free radical generation in rabbit kid- 
ney-cortex tubules. Molecular and Cellular Biochemistry, 
261, 91-98. doi:10.1023/B:MCBI.0000028742.83086.43 
[38] Frances, D.E., Ronco, M.T., et al. (2010) Hyperglycemia 
induces apoptosis in rat liver through the increase of hy- 
droxyl radical: New insights into the insulin effect. Jour- 
nal of Endocrinology, 205, 187-200.  
doi:10.1677/JOE-09-0462 
[39] Littlejohn, A.F., Tucker, S.J., et al. (2003) Modulation by 
caspases of tumor necrosis factor-stimulated c-Jun N-ter- 
minal kinase activation but not nuclear factor-kappaB 
signaling. Biochemical Pharmacology, 65, 91-99.  
doi:10.1016/S0006-2952(02)01443-0  
[40] McFarlane, S.M., Pashmi, G., et al. (2002) Differential 
activation of nuclear factor-kappaB by tumour necrosis 
factor receptor subtypes. TNFR1 predominates whereas 
TNFR2 activates transcription poorly. FEBS Letters, 515, 
119-126. doi:10.1016/S0014-5793(02)02450-X 
[41] Srinivasan, K. and Ramarao, P. (2007) Animal models in 
type 2 diabetes research: An overview. The Indian Jour- 
nal of Medical Research, 125, 451-472.  
http://www.ncbi.nlm.nih.gov/pubmed/17496368  
[42] Joyce, D., Albanese, C., et al. (2001) NF-kappaB and 
cell-cycle regulation: The cyclin connection. Cytokine & 
Growth Factor Reviews, 12, 73-90.  
doi:10.1016/S1359-6101(00)00018-6 
[43] Yamamoto, Y. and Gaynor, R.B. (2004) IkappaB kinases: 
Key regulators of the NF-kappaB pathway. Trends in 
Biochemical Sciences, 29, 72-79.  
doi:10.1016/j.tibs.2003.12.003 
[44] Lim, J.W., Kim, H., et al. (2001) NF-kappaB, inducible 
nitric oxide synthase and apoptosis by Helicobacter py- 
lori infection. Free Radical Biology & Medicine, 31, 355- 
366. doi:10.1016/S0891-5849(01)00592-5 
[45] Chen, Y.W., Chenier, I., et al. (2011) High glucose pro- 
motes nascent nephron apoptosis via NF-kappaB and p53 
pathways. American Journal of Physiology Renal Physi- 
ology, 300, F147-156. doi:10.1152/ajprenal.00361.2010 
[46] Karin, M. and Greten, F.R. (2005) NF-kappaB: Linking 
inflammation and immunity to cancer development and 
progression. Nature Reviews. Immunology, 5, 749-759.  
[47] Yang, W.S., Seo, J.W., et al. (2008) High glucose-in- 
duced NF-kappaB activation occurs via tyrosine phos- 
phorylation of IkappaBalpha in human glomerular endo- 
thelial cells: Involvement of Syk tyrosine kinase. Ameri- 
can Journal of Physiology Renal Physiology, 294, F1065- 
F1075. doi:10.1152/ajprenal.00381.2007 
[48] Zimmermann, K.C. and Green, D.R. (2001) How cells 
die: Apoptosis pathways. The Journal of Allergy and 
Clinical Immunology, 108, S99-S103.  
doi:10.1067/mai.2001.117819 
[49] Curtin, J.F., Donovan, M., et al. (2002) Regulation and 
measurement of oxidative stress in apoptosis. Journal of 
Immunological Methods, 265, 49-72.  
doi:10.1016/S0022-1759(02)00070-4 
[50] Lennon, S.V., Martin, S.J., et al. (1991) Dose-dependent 
induction of apoptosis in human tumour cell lines by 
widely diverging stimuli. Cell Proliferation, 24, 203-214. 
doi:10.1111/j.1365-2184.1991.tb01150.x  
Copyright © 2013 SciRes.                                                                       OPEN ACCESS 
D. E. Francés et al. / J. Biomedical Science and Engineering 6 (2013) 645-653 652 
[51] Magowan, G. and Price, D.J. (1996) Trophic and out- 
growth-promoting effects of K(+)-induced depolarization 
on developing thalamic cells in organotypic culture. 
Neuroscience, 74, 1045-1057.  
http://www.ncbi.nlm.nih.gov/pubmed/8895873  
[52] Suzuki, Y., Ono, Y., et al. (1998) Rapid and specific 
reactive oxygen species generation via NADPH oxidase 
activation during Fas-mediated apoptosis. FEBS Letters, 
425, 209-212. doi:10.1016/S0014-5793(98)00228-2 
[53] Bai, J. and Odin, J.A. (2003) Apoptosis and the liver: 
Relation to autoimmunity and related conditions. Auto- 
immunity Reviews, 2, 36-42.  
doi:10.1016/S1568-9972(02)00125-8 
[54] Ronco, M.T., de Alvarez, M.L., et al. (2002) Modulation 
of balance between apoptosis and proliferation by lipid 
peroxidation (LPO) during rat liver regeneration. Mo- 
lecular Medicine, 8, 808-817.  
http://www.ncbi.nlm.nih.gov/pubmed/12606815  
[55] Park, K.S., Kim, J.H., et al. (2001) Effects of insulin and 
antioxidant on plasma 8-hydroxyguanine and tissue 
8-hydroxydeoxyguanosine in streptozotocin-induced dia- 
betic rats. Diabetes, 50, 2837-2841.  
doi:10.2337/diabetes.50.12.2837 
[56] Green, D.R. and Reed, J.C. (1998) Mitochondria and 
apoptosis. Science, 281, 1309-1312.  
doi:10.1126/science.281.5381.1309 
[57] Liu, X., Kim, C.N., et al. (1996) Induction of apoptotic 
program in cell-free extracts: Requirement for dATP and 
cytochrome c. Cell, 86, 147-157. 
doi:10.1016/S0092-8674(00)80085-9  
[58] Nakagami, H., Morishita, R., et al. (2002) Hepatocyte 
growth factor prevents endothelial cell death through in- 
hibition of bax translocation from cytosol to mitochon- 
drial membrane. Diabetes, 51, 2604-2611.  
doi:10.2337/diabetes.51.8.2604 
[59] Chatila, R. and West, A.B. (1996) Hepatomegaly and 
abnormal liver tests due to glycogenosis in adults with 
diabetes. Medicine, 75, 327-333.  
doi:10.1097/00005792-199611000-00003 
[60] Harrison, S.A. (2006) Liver disease in patients with dia- 
betes mellitus. Journal of Clinical Gastroenterology, 40, 
68-76. doi:10.1097/01.mcg.0000190774.91875.d2 
[61] McLennan, S.V., Heffernan, S., et al. (1991) Changes in 
hepatic glutathione metabolism in diabetes. Diabetes, 40, 
344-348. http://www.ncbi.nlm.nih.gov/pubmed/1671844  
[62] Saxena, A.K., Srivastava, P., et al. (1993) Impaired anti- 
oxidant status in diabetic rat liver. Effect of vanadate. 
Biochemical Pharmacology, 45, 539-542.  
http://www.ncbi.nlm.nih.gov/pubmed/8442752  
[63] Bell, D.S. and Allbright, E. (2007) The multifaceted as- 
sociations of hepatobiliary disease and diabetes. Endo- 
crine Practice, 13, 300-312.  
http://www.ncbi.nlm.nih.gov/pubmed/17599864  
[64] Hinokio, Y., Suzuki, S., et al. (1999) Oxidative DNA 
damage in diabetes mellitus: Its association with diabetic 
complications. Diabetologia, 42, 995-998.  
[65] Ingaramo, P.I., Ronco, M.T., et al. (2011) Tumor necrosis 
factor alpha pathways develops liver apoptosis in type 1 
diabetes mellitus. Molecular Immunology, 48, 1397-1407.  
[66] Suzuki, S., Hinokio, Y., et al. (1999) Oxidative damage 
to mitochondrial DNA and its relationship to diabetic 
complications. Diabetes Research and Clinical Practice, 
45, 161-168.  
http://www.ncbi.nlm.nih.gov/pubmed/10588369  
[67] Jones, B.E., Lo, C.R., et al. (2000) Hepatocytes sensitized 
to tumor necrosis factor-alpha cytotoxicity undergo 
apoptosis through caspase-dependent and caspase-inde- 
pendent pathways. The Journal of Biological Chemistry, 
275, 705-712.  
http://www.ncbi.nlm.nih.gov/pubmed/10617670  
[68] Koniaris, L.G., McKillop, I.H., et al. (2003) Liver regen- 
eration. Journal of the American College of Surgeons, 
197, 634-659.  
[69] Patel, T., Steer, C.J., et al. (1999) Apoptosis and the liver: 
A mechanism of disease, growth regulation, and carcino- 
genesis. Hepatology, 30, 811-815.  
[70] Hsu, H., Shu, H.B., et al. (1996) TRADD-TRAF2 and 
TRADD-FADD interactions define two distinct TNF re- 
ceptor 1 signal transduction pathways. Cell, 84, 299-308.  
doi:10.1016/S0092-8674(00)80984-8 
[71] Cottet, S., Dupraz, P., et al. (2002) CFLIP protein pre- 
vents tumor necrosis factor-alpha-mediated induction of 
caspase-8-dependent apoptosis in insulin-secreting be- 
taTc-Tet cells. Diabetes, 51, 1805-1814.  
http://www.ncbi.nlm.nih.gov/pubmed/12031968  
[72] Zhao, Y., Ding, W.X., et al. (2003) Bid activates multiple 
mitochondrial apoptotic mechanisms in primary hepato- 
cytes after death receptor engagement. Gastroenterology, 
125, 854-867.  
http://www.ncbi.nlm.nih.gov/pubmed/12949730  
[73] Zhao, Y., Li, S., et al. (2001) Activation of pro-death 
Bcl-2 family proteins and mitochondria apoptosis path- 
way in tumor necrosis factor-alpha-induced liver injury. 
The Journal of Biological Chemistry, 276, 27432-27440.  
[74] Wullaert, A., Heyninck, K., et al. (2006) Mechanisms of 
crosstalk between TNF-induced NF-kappaB and JNK ac- 
tivation in hepatocytes. Biochemical Pharmacology, 72, 
1090-1101. doi:10.1016/j.bcp.2006.07.003 
[75] Boden, G. She,, P., et al. (2005) Free fatty acids produce 
insulin resistance and activate the proinflammatory nu- 
clear factor-kappaB pathway in rat liver. Diabetes, 54, 
3458-3465. 
http://www.ncbi.nlm.nih.gov/pubmed/16306362  
[76] Romagnoli, M., Gomez-Cabrera, M.C., et al. (2010) 
Xanthine oxidase-induced oxidative stress causes active- 
tion of NF-kappaB and inflammation in the liver of type I 
diabetic rats. Free Radical Biology and Medicine, 49, 
171-177. doi:10.1016/j.freeradbiomed.2010.03.024 
[77] Powell, L.A., Warpeha, K.M., et al. (2004) High glucose 
decreases intracellular glutathione concentrations and 
upregulates inducible nitric oxide synthase gene expres-
sion in intestinal epithelial cells. Journal of Molecular 
Endocrinology, 33, 797-803. doi:10.1677/jme.1.01671 
[78] Stadler, K., Bonini, M.G., et al. (2008) Involvement of 
inducible nitric oxide synthase in hydroxyl radical-medi- 
ated lipid peroxidation in streptozotocin-induced diabetes. 
Copyright © 2013 SciRes.                                                                       OPEN ACCESS 
D. E. Francés et al. / J. Biomedical Science and Engineering 6 (2013) 645-653 
Copyright © 2013 SciRes.                                                                      
653
 OPEN ACCESS 
Free Radical Biology & Medicine, 45, 866-874.  
[79] Noh, H., Ha, H., et al. (2002). High glucose increases 
inducible NO production in cultured rat mesangial cells. 
Possible role in fibronectin production. Nephron, 90, 
78-85. http://www.ncbi.nlm.nih.gov/pubmed/11744809  
 
 
 
 
